**Abstract**

**Background:** Antidepressant medications are first-line pharmacological treatment for obsessive-compulsive and related disorders. However, approximately 50% of patients show poor/minimal response to these medications.

**Objective:** We aimed to investigate the genetics of antidepressant response in obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) patients.

**Methods:** We investigated 32 SNPs across 14 genes and their regulatory regions with antidepressant response using a custom-made 32-SNP QuantStudio Flex Real-Time PCR System Chip in 222 OCD individuals. Individuals were grouped into responders and non-responders using the Clinical Global Impression -- Improvement (CGI-I) scale. Pearson χ^2^ test was performed to detect differences in the number of responders versus non-responders across genotype groups. For the BDD sample, we genotyped 10 SNPs across nine genes in 35 BDD individuals and response was determined using CGI-I.

**Results:** For OCD, interesting associations (P\<0.05) were detected for the serotonin genes, *HTR2A* and *HTR1B* in antidepressant response. For BDD, we did not detect any significant associations in any of the tested SNPs.

**Conclusions:** The serotonergic system genes may be clinically useful in predicting treatment resistance versus response in patients with OCD. Future study with larger sample size is required to replicate these findings.
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